JP3088680B2 - Synthetic method of antitumor substance by intestinal bacteria and ray bacteria - Google Patents

Synthetic method of antitumor substance by intestinal bacteria and ray bacteria

Info

Publication number
JP3088680B2
JP3088680B2 JP09124632A JP12463297A JP3088680B2 JP 3088680 B2 JP3088680 B2 JP 3088680B2 JP 09124632 A JP09124632 A JP 09124632A JP 12463297 A JP12463297 A JP 12463297A JP 3088680 B2 JP3088680 B2 JP 3088680B2
Authority
JP
Japan
Prior art keywords
bacteria
ray
synthetic method
antitumor substance
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP09124632A
Other languages
Japanese (ja)
Other versions
JPH10276790A (en
Inventor
基博 中島
Original Assignee
基博 中島
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 基博 中島 filed Critical 基博 中島
Priority to JP09124632A priority Critical patent/JP3088680B2/en
Publication of JPH10276790A publication Critical patent/JPH10276790A/en
Application granted granted Critical
Publication of JP3088680B2 publication Critical patent/JP3088680B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】この発明は腸内菌、レイ菌に
よる抗腫瘍物質の合成法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention
A method for synthesizing an antitumor substance.

【0002】[0002]

【従来の技術】従来の抗ガン剤は化学合成されたもの
か、非腫瘍生物からの抽出物である。腫瘍及び腫瘍産生
物を菌により分解せしめ、抗腫瘍物質を合成したことは
未だ報告されていない。
BACKGROUND OF THE INVENTION Conventional anti-cancer drugs are chemically synthesized or are extracts from non-tumor organisms. It has not yet been reported that tumors and tumor products were decomposed by bacteria to synthesize antitumor substances.

【0003】[0003]

【発明が解決しようとする課題】本発明は対称とする腫
瘍及び腫瘍産生物をレイ菌、大腸菌等の腸内菌により分
解せしめ、対称腫瘍に対する抗腫瘍物質(変性及び増殖
抑制物質)を合成することである。この手法を用いて癌
患者を助けることが可能である。
DISCLOSURE OF THE INVENTION According to the present invention, tumors and tumor products to be symmetric are decomposed by intestinal bacteria such as Ley bacteria and Escherichia coli to synthesize antitumor substances (denaturation and growth inhibitory substances) against symmetric tumors. That is. This technique can be used to help cancer patients.

【0004】[0004]

【課題を解決するための手段】請求項1の発明の抗腫瘍
物質の合成法は、エールリッヒ腫瘍細胞及びその培養液
を加熱滅菌し、腸内菌、レイ菌を移植し36.5℃前後
で約一週間培養するものである。
The antitumor according to the first aspect of the present invention.
The method of synthesizing the substance is based on Ehrlich tumor cells and their culture solution.
Is heat-sterilized and transplanted with intestinal bacteria and Ley bacteria at around 36.5 ° C.
For about one week.

【0005】[0005]

【発明の実施の形態】[合成方法.]腫瘍細胞(この実
験ではエールリッヒ腫瘍細胞を用いている。)及びその
培養液500mlを加熱滅菌し上記細菌を移植し36.
5℃前後で約一週間培養する。 [温度条件の理由.]30℃で細菌を培養したときと3
7℃で培養したとき、菌の働きは異なっている。例.レ
イ菌は30℃ではプロデイギオジンを産生する(赤色)
が37℃では、白色菌コロニーをつくる(プロデイギオ
ジンを作らず)。又、生体体表温度は36.5℃前後で
ある。
DESCRIPTION OF THE PREFERRED EMBODIMENTS [Synthesis method. 36. Tumor cells (Ehrlich tumor cells are used in this experiment) and 500 ml of a culture thereof are heat-sterilized, and the above bacteria are transplanted.
Incubate at about 5 ° C for about one week. [Reason for temperature condition. ] When the bacteria were cultured at 30 ° C and 3
When cultured at 7 ° C., the function of the bacteria is different. Example. Ray produces prodigiosin at 30 ° C (red)
At 37 ° C., produce white bacterial colonies (no prodigiodin). The surface temperature of the living body is about 36.5 ° C.

【0006】[生成物の抽出方法] 以下、抽出精製法を順に従い例挙する。 培養液を加
熱滅菌しアルコールを添加(最終濃度80%)後、東洋
ろ紙でろ過する。アルコールを蒸発せしめ室温にて再度
ろ過して非水溶性物を除く。 アセトンを添加(アセ
トン最終濃度80%)後、アセトン凝固物除去後、アセ
トンを蒸発除去する。 クロロホルムを原液の2倍量
加え、よく振盪してクロロホルム凝固物を除去後、水層
を除去し、このクロロホルム層を10℃以下の所に置
き、生成する白濁凝固物をろ紙にて分別し、このろ紙を
水中に入れてクロロホルム可溶性寒冷凝集物を抽出す
る。 クロロホルム可溶性寒冷凝集物含有液の2倍量
のエーテルを加え、よく振盪してエーテル可溶物を移行
せしめ、後にエーテルを除去する。 かくして得られ
た原液をブタノール:氷酢酸:水=4:1:2系にてペ
ーパークロマト下降法にて展開しRf=0.16前後に
ニンヒドリン反応陽性物を得る(原分解材料原液500
mlの時は上記物質含有液2mlを作成して実験を行な
う)。尚、添付する写真(図1、図2参照。)の様な結
晶構造を示している。
[Production Extraction Method] Hereinafter, extraction and purification methods will be exemplified in order. The culture solution is heat-sterilized, alcohol is added (final concentration: 80%), and the solution is filtered through Toyo filter paper. The alcohol is evaporated and filtered again at room temperature to remove water-insoluble materials. After addition of acetone (acetone final concentration: 80%), acetone is removed by coagulation, and the acetone is evaporated off. After adding chloroform twice as much as the stock solution and shaking well to remove chloroform coagulation, the aqueous layer was removed, and the chloroform layer was placed at a temperature of 10 ° C. or lower, and the formed cloudy coagulation was separated by filter paper. The filter paper is placed in water to extract chloroform-soluble cold aggregates. Ether is added twice as much as the chloroform-containing solution containing the cold aggregate, and the mixture is shaken well to transfer the ether-soluble matter, and then the ether is removed. The stock solution thus obtained is developed with a butanol: glacial acetic acid: water = 4: 1: 2 system by a paper chromatography descending method to obtain a ninhydrin reaction-positive substance around Rf = 0.16 (raw material stock solution 500).
When the amount is ml, prepare 2 ml of the above-mentioned substance-containing solution and conduct the experiment). In addition, the crystal structure as shown in the attached photographs (see FIGS. 1 and 2) is shown.

【0007】今回発見せる物質の性質をまとめると、非
熱凝固性、アルコール、アセトン、クロロホルム可溶
性、エーテル非可溶性且つクロロホルム溶解中で寒冷凝
集性を有する。以上の抽出法においてクロロホルム可溶
物を寒冷凝集させる手法を見いだしたのが最大の特徴で
ある。
[0007] The properties of the substance discovered this time can be summarized as follows: non-coagulable, soluble in alcohol, acetone and chloroform, insoluble in ether, and cold-coagulating in chloroform. The most characteristic feature of the above extraction method is that a method of cold-aggregating chloroform-soluble matter has been found.

【0008】[使用実例と結果] (実例)エールリッヒ細胞腹腔内移植3日目のマウス
(実験体)に3日に一度の皮下注射にて0.5mlづつ
前記せる抽出液を投与する。エールリッヒ細胞移植後1
1.14.17日目に腹水を採取し、ギムザ染色にて細
胞を観察した。上記実験手順を図3に示す。
[Examples of Use and Results] (Example) A mouse (experimental body) on the third day of Ehrlich cell intraperitoneal transplantation is injected with 0.5 ml of the above extract by subcutaneous injection once every three days. After Ehrlich cell transplantation 1
1.14. Ascites was collected on day 17 and the cells were observed by Giemsa staining. The above experimental procedure is shown in FIG .

【0009】(結果)細胞の破壊が添付せる写真(図4
〜図8参照。)の様に観察され、細胞が膨化破裂してい
る核は結合を粗にしている。
(Results) Photographs attached to cell destruction (FIG. 4)
See FIG. ), And the nucleus in which the cells are swollen and ruptured loosely binds.

【0010】なお、図4の写真は、細胞が一様に染色し
ている(対称)場合が示されている。図5の写真は、テ
スト液3回投与後2日目のもので、細胞膜が膨化しはじ
めている状態が示されている。図6の写真は、テスト液
投与後5日目のもので、細胞の膨化が著明になり、一部
の細胞が破れている状態が示されている。図7の写真
は、テスト液3回投与後8日目のもので、細胞が核の萎
縮を伴うことなく破裂し、中央と右端にその破片がみら
れる。図8の写真は、細胞膜を失い、核が分解している
状態が示されている。
The photograph in FIG. 4 shows that the cells are stained uniformly.
Is shown (symmetric). The photograph in FIG.
On the second day after three administrations of the strike solution, the cell membrane swells and
Is shown. The photograph in FIG. 6 shows the test solution
5 days after administration, swelling of cells became remarkable, and
The cells are shown torn. Picture of FIG.
Is on the 8th day after three administrations of the test solution.
Ruptures without shrinkage, with debris visible at center and right end
It is. The photograph in FIG. 8 shows that the cell membrane has been lost and the nucleus has been decomposed.
The state is shown.

【0011】従来の抗腫瘍物質は腫瘍細胞の増殖抑制を
主としていたが、この出願に係わる物質は、肺瘍細胞の
破壊を作用の主としている所が特徴である。尚、腫瘍細
胞の生成量は対称群に対し、その1/2以下に抑制され
る。実験体の各種他臓器の変性は認められなかった。
[0011] Conventional antitumor substances mainly suppress the growth of tumor cells, but the substance according to the present application is characterized in that it mainly acts to destroy lung ulcer cells. Note that the amount of tumor cells generated is suppressed to 1 / or less of the symmetric group. No degeneration of various other organs of the experimental body was observed.

【0012】以上のように、目標腫瘍細胞に対してその
腫瘍細胞及びその産生物を細菌により分解せしめて抗腫
瘍性物質を生合成する方法は未だその報告例をみない。
化学的性質を用いて資料を精製する方法はすでに確立さ
れているが、前記抽出液方法中にのべたごとく、クロロ
ホルム可溶性で且つ寒冷凝集をきたす性質を利用して目
的物質を取得したのがこの精製方法の一大特徴である。
ここに請求された合成法と精製法を利用して対腫瘍療法
の新しい分野が開かれると考える。
As described above, there is no report on a method of biosynthesizing an antitumor substance by decomposing a tumor cell and its product by a bacterium with respect to a target tumor cell.
Although a method for purifying materials using chemical properties has already been established, the target substance was obtained using the property of being soluble in chloroform and causing cold aggregation, as described in the extract method. This is a major feature of the purification method.
We believe that a new field of antitumor therapy will be opened using the synthetic and purification methods claimed herein.

【図面の簡単な説明】[Brief description of the drawings]

【図1】柱状結晶を示す顕微鏡写真を示す図である。FIG. 1 is a diagram showing a micrograph showing a columnar crystal.

【図2】結晶の集積している状態を示す顕微鏡写真を示
す図である。
FIG. 2 is a diagram showing a micrograph showing a state in which crystals are accumulated.

【図3】使用実例の手順を示す図である。FIG. 3 is a diagram showing a procedure of a usage example.

【図4】染色した細胞を示す対称の顕微鏡写真を示す図
である。
FIG. 4 shows a symmetric micrograph showing the stained cells.

【図5】テスト液投与後2日の細胞の顕微鏡写真を示す
図である。
FIG. 5 is a diagram showing a micrograph of cells two days after administration of a test solution.

【図6】テスト液投与後5日目の顕微鏡写真を示す図で
ある。
FIG. 6 is a diagram showing a micrograph 5 days after administration of a test solution.

【図7】テスト液投与後8日目の顕微鏡写真を示す図で
ある。
FIG. 7 is a diagram showing a micrograph on the 8th day after test solution administration.

【図8】細胞膜を失い、核の分解した細胞の顕微鏡写真FIG. 8 is a micrograph of a cell whose cell membrane has been lost and whose nucleus has been decomposed.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI (C12P 1/04 C12R 1:43) ──────────────────────────────────────────────────の Continued on front page (51) Int.Cl. 7 Identification code FI (C12P 1/04 C12R 1:43)

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 エールリッヒ腫瘍細胞及びその培養液を
加熱滅菌し、腸内菌、レイ菌を移植し36.5℃前後で
約一週間培養する抗腫瘍物質の合成法。
1. An Ehrlich tumor cell and its culture solution
Sterilize by heating, inoculate with intestinal bacteria and ray bacteria
A method for synthesizing an antitumor substance that is cultured for about one week.
JP09124632A 1997-04-07 1997-04-07 Synthetic method of antitumor substance by intestinal bacteria and ray bacteria Expired - Lifetime JP3088680B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP09124632A JP3088680B2 (en) 1997-04-07 1997-04-07 Synthetic method of antitumor substance by intestinal bacteria and ray bacteria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP09124632A JP3088680B2 (en) 1997-04-07 1997-04-07 Synthetic method of antitumor substance by intestinal bacteria and ray bacteria

Publications (2)

Publication Number Publication Date
JPH10276790A JPH10276790A (en) 1998-10-20
JP3088680B2 true JP3088680B2 (en) 2000-09-18

Family

ID=14890227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09124632A Expired - Lifetime JP3088680B2 (en) 1997-04-07 1997-04-07 Synthetic method of antitumor substance by intestinal bacteria and ray bacteria

Country Status (1)

Country Link
JP (1) JP3088680B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343153B2 (en) 2005-05-12 2009-10-14 基博 中島 Method for producing antitumor composition

Also Published As

Publication number Publication date
JPH10276790A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
DE1803987A1 (en) New, physiologically active peptidolipid and process for its production
NL8000291A (en) PROCESS FOR PREPARING INTERFERON TYPE II, THE THERAPEUTIC USE OF INTERFERON TYPE II AND THE BASIC PHARMACEUTICAL PREPARATIONS.
CH664897A5 (en) PURIFIED, DETOXICATED ENDOTOXIN CONTAINING PHARMACEUTICAL COMPOSITION.
US4793996A (en) Method of making soybean extract inhibitor
JP3088680B2 (en) Synthetic method of antitumor substance by intestinal bacteria and ray bacteria
JPH0360804B2 (en)
DE2829975A1 (en) ANTITUMOR ACTIVE SUBSTANCE, ITS PRODUCTION AND USE
JPH08143462A (en) Immunostimulating agent and antitumor agent
Vesely et al. Pea phytohemagglutinin selective agglutination of tumour cells
DE3784768T2 (en) USE OF COMPOSITIONS BASED ON CROTOXIN, FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF CARCINOMAS.
JP3413220B2 (en) Skin roughness improver
JPS5982395A (en) Anthracycline compound, its preparation and use
DE2639410C2 (en) Polypeptide VI-7501 with anti-tumor activity
JP3172599B2 (en) Cell activator
RU2069696C1 (en) Producer of antitumor melanin-containing preparation
CN115804851B (en) Cowpea chlorotic mottle virus-polypeptide complex with bone targeting function and application thereof in osteoporosis treatment
Wallace Effect of delayed addition of irradiated cells to small viable tumor inocula
DE3236298C2 (en)
DE1617886A1 (en) Process for the preparation of drugs with selective tropism against cancer and certain organs
JP3117964B2 (en) Antitumor substance
JPS63196521A (en) Tumor cell disorder factor inducer
TWI629361B (en) Hyaluronidase inhibitor from symbiotic fermented product and application thereof
US20060093628A1 (en) Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immonomodulator, its production process and formulation
JPH0565490B2 (en)
SU687120A1 (en) Method of obtaining antiviral preparation from yeast

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313532

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100714

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100714

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110714

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120714

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130714

Year of fee payment: 13

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term